ARCH Venture Management, LLC Diversified Active

CIK: 0001274403 · Show all filings

Period: Q2 2022 (← Previous) (Next →)

Filing Date: Aug 15, 2022

Total Value ($000): $820,637 (100.0% shares, 0.0% debt)

Holdings (10)

— KARUNA THERAPEUTICS, INC. 44.9%

Value ($000) $368,507 Shares 2,912,872 Est. Cost $131.00 Unrealized —

— EQRX, INC. 20.8%

Value ($000) $170,413 Shares 36,335,375 Est. Cost $6.82 Unrealized —

DNLI DENALI THERAPEUTICS, INC. 18.5%

Value ($000) $152,116 Shares 5,168,749 Est. Cost $26.20 Unrealized 0.0%

ERAS ERASCA, INC. 7.5%

Value ($000) $61,579 Shares 11,055,554 Est. Cost $17.12 Unrealized -61.8%

— VERVE THERAPEUTICS, INC. 4.7%

Value ($000) $38,335 Shares 2,508,809 Est. Cost $36.87 Unrealized —

— SINGULAR GENOMICS SYSTEMS, INC. 1.8%

Value ($000) $14,512 Shares 3,798,926 Est. Cost $11.56 Unrealized —

— REVOLUTION HEALTHCARE ACQUISITION CORP. 1.6%

Value ($000) $13,260 Shares 1,357,237 Est. Cost $9.77 Unrealized —

— METACRINE, INC. 0.2%

Value ($000) $1,470 Shares 2,940,503 Est. Cost $0.61 Unrealized —

— RUBIUS THERAPEUTICS, INC. 0.0%

Value ($000) $298 Shares 349,908 Est. Cost $16.08 Unrealized —

— ZYMERGEN INC. 0.0%

Value ($000) $147 Shares 119,205 Est. Cost $6.69 Unrealized —

Ticker	Issuer	Shares	Value ($000)	%	Est. Cost	Unrealized	Class	CUSIP
—	KARUNA THERAPEUTICS, INC.	2,912,872	$368,507	44.9%	$131.00	—	COM	48576A100
—	EQRX, INC.	36,335,375	$170,413	20.8%	$6.82	—	COM	26886C107
DNLI	DENALI THERAPEUTICS, INC.	5,168,749	$152,116	18.5%	$26.20	0.0%	COM	24823R105
ERAS	ERASCA, INC.	11,055,554	$61,579	7.5%	$17.12	-61.8%	COM	29479A108
—	VERVE THERAPEUTICS, INC.	2,508,809	$38,335	4.7%	$36.87	—	COM	92539P101
—	SINGULAR GENOMICS SYSTEMS, INC.	3,798,926	$14,512	1.8%	$11.56	—	COM	82933R100
—	REVOLUTION HEALTHCARE ACQUISITION CORP.	1,357,237	$13,260	1.6%	$9.77	—	COM	76155Y108
—	METACRINE, INC.	2,940,503	$1,470	0.2%	$0.61	—	COM	59101E103
—	RUBIUS THERAPEUTICS, INC.	349,908	$298	0.0%	$16.08	—	COM	78116T103
—	ZYMERGEN INC.	119,205	$147	0.0%	$6.69	—	COM	98985X100